Stockwinners Market Radar for December 23, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
BAC... | Hot Stocks19:30 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. President Donald Trump's Treasury secretary called America's top bankers and said he got reassurances about the health of the nation's banks amid an ongoing rout on Wall Street, according to Reuters. The Treasury said in a statement that Steven Mnuchin talked with the chief executives of Bank of America (BAC), Citi (C), Goldman Sachs (GS), JP Morgan Chase (JPM), Morgan Stanley (MS) and Wells Fargo (WFC). "The CEOs confirmed that they have ample liquidity available for lending," Mnuchin said, adding that he "also confirmed that they have not experienced any clearance or margin issues and that the markets continue to function properly." The Treasury also added that Mnuchin will convene a call on Monday with the president's Working Group on Financial Markets, which includes Washington's main stewards of the U.S. financial system and is sometimes referred to as the "Plunge Protection Team," Reuters noted. 2. Kraft Heinz (KHC) and Mondelez (MDLZ) have been short-listed to participate in the second round of Campbell Soup's (CPB) auction of its international business, according to Reuters, citing people familiar with the matter. Based on the first-round bids received, Campbell Soup could fetch close to $3B for its international business, sources added. Bain Capital, KKR (KKR) and FinTrek Capital Hong Kong also made the shortlist to participate in the second round of the auction for Campbell Soup's international business, the publication added. 3. An expected wave of initial public offerings by giant, well-known companies like Lyft (LYFT) and Uber (UBER) could open opportunities for investors to jump into businesses with leading positions in winner-take-all markets, potentially becoming the next Amazon (AMZN) or Facebook (FB), Daren Fonda and Jon Swartz wrote in this week's edition of Barron's. Yet investors should temper their expectations as steep private valuations could make the stocks disappointing, at least in the near-term, they added. 4. AT&T (T) subsidiary Warner Bros' "Aquaman" won the pre-Christmas U.S. box office with $67.4M from 4,125 theaters. Directed by James Wan, "Aquaman" stars Jason Momoa in the titular role alongside Amber Heard, Willem Dafoe, Patrick Wilson and Dolph Lundgren. The movie earned an A- CinemaScore and sports a 64% Rotten Tomatoes score. 5. Morgan Stanley, British American Tobacco (BTI), Philip Morris (PM), Henkel (HENKY), Danone (DANOY), Cie Financiere Richemont (CFRUY), and BASF (BASFY) saw positive mentions in Barron's.
|
T... | Hot Stocks17:48 EDT Box Office Battle: 'Aquaman' opens to $67.4M, beats 'Mary Poppins' - AT&T (T) subsidiary Warner Bros' "Aquaman" won the pre-Christmas U.S. box office with $67.4M from 4,125 theaters. Directed by James Wan, "Aquaman" stars Jason Momoa in the titular role alongside Amber Heard, Willem Dafoe, Patrick Wilson and Dolph Lundgren. The movie earned an A- CinemaScore and sports a 64% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: Disney's (DIS) musical "Mary Poppins Returns" placed number two in its debut weekend with $22.2M from 4,090 locations for a five-day opening of $31M. Behind it was Viacom (VIAB) subsidiary Paramount's "Bumblebee," earning $21M from 3,550 theaters in its debut weekend. Sony's (SNE) "Spider-Man: Into the Spider-Verse" placed number four with $16.5M for a 10-day total of $65M. Rounding out the top five, Warner Bros' "The Mule" grossed an estimated $9.3M for a domestic total of $35M. Other publicly traded companies in filmmaking include Comcast (CMCSA), 21st Century Fox's (FOX, FOXA) and Lionsgate's (LGF.A, LGF.B).
|
ACOR | Hot Stocks12:31 EDT Acorda Therapeutics announces FDA approval of INBRIJA - Acorda Therapeutics announced that the U.S. Food and Drug Administration approved INBRIJA for intermittent treatment of OFF episodes in people with Parkinson's disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson's symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa, the standard oral baseline Parkinson's treatment. FDA approval of INBRIJA was based on a clinical program that included approximately 900 people with Parkinson's on a carbidopa/levodopa regimen experiencing OFF periods. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks.
|